FILE PHOTO: The company’s logo is seen at the new cell and gene therapy factory of Swiss drugmaker Novartis in Stein, Switzerland, November 28, 2019. REUTERS/Arnd Wiegmann
ZURICH (Reuters) – Swiss drugmaker Novartis is abandoning development of its drug fevipiprant in asthma after the medicine failed key trials.
“The totality of these results do not support further development of fevipiprant in asthma,” the company said on Monday in a statement.
Reporting by John Miller; Editing by Tassilo Hummel
Our Standards:The Thomson Reuters Trust Principles.
source: reuters.com